-
UPCOMING EVENTS
SMC attend BIO One-on-One Partnering™ in Bio Asia Taiwan!
2022.07.13
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One PartneringTM in Bio Asia Taiwan from July 27th to 31th.
-
UPCOMING EVENTS
2022.07.06
Today, we are pleased to announce the acceptance of our abstract on our NASH-hepatocellular carcinoma (HCC) model at the 29th convention of The Japanese Society for the Research of Hepatic Cells, which is to be held on August 25th and 26th.
-
PUBLICATION
GN Corporation publication in Journal of Clinical and Experimental Hepatology
2022.06.30
SMC announces that GN Corporation Clinical and Experimental Hepatology (Japan) has published the results of a study using STAM™ mouse model in Clinical and Experimental Hepatology.
-
PUBLICATION
Esperion Therapeutics's publication in Cell Metabolism
2022.06.21
SMC announces that Esperion Therapeutics (MI, USA) has published the results of a study using STAM™ mouse model in Cell Metabolism.
-
PRODUCTS AND SERVICES
Potential NASH biomarker in NASH-HCC model
2022.06.10
We would like to introduce the data for a serological marker from our NASH model (STAM™ model).
-
PUBLICATION
Drug efficacy studies in NASH mouse model
2022.05.23
We would like to introduce a study published by our client using our proprietary non-alcoholic steatohepatitis (NASH) model called STAM™ (Ikewaki et al., bioRxiv, 2021).
-
PRODUCTS AND SERVICES
Introducing our new model: DDC-induced liver injury model
2022.05.10
We introduce the 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced liver injury model*, a well-known model of cholestatic liver disease and a new model we have started offering our services as.
-
UPCOMING EVENTS
Reserve a non-clinical pharmacology consultation with us at BIO KOREA 2022!
2022.04.29
We will join BIO KOREA 2022 International Convention, one of the biggest bio-health conventions in Asia.
-
NEWS RELEASE
Introduction of the paper using our UUO model
2022.04.16
We would like to introduce a paper published by our client using Chronic kidney disease model.
-
NEWS RELEASE
2022.04.01
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunction-associated fatty liver disease is a new concept in the understanding of fatty liver disease and it’s pathogenesis.
-
NEWS RELEASE
Drug efficacy studies using multiple mouse models to replicate human disease.
2022.03.16
To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of NASH.
-
NEWS RELEASE
The comparison of NASH-HCC and other HCC models
2022.03.11
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020.
